Published in BMC Neurol on June 17, 2010
Editorial neuroAIDS review. AIDS (2011) 1.10
Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study. AIDS Res Ther (2011) 0.85
Medical management of epileptic seizures: challenges and solutions. Neuropsychiatr Dis Treat (2016) 0.75
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (2008) 2.21
The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med (2004) 1.89
Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther (2005) 1.51
Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther (2006) 1.50
Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence. Curr Top Microbiol Immunol (1995) 1.29
A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol (2004) 1.24
Frequency of seizures and epilepsy in neurological HIV-infected patients. Seizure (2007) 1.21
Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics (2007) 1.16
Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology (2006) 1.16
Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biol Psychiatry (2003) 1.14
Some common issues in the use of antiepileptic drugs. Semin Neurol (2002) 1.14
Lentivirus infection in the brain induces matrix metalloproteinase expression: role of envelope diversity. J Virol (2000) 1.12
HIV-associated neuropathic pain: epidemiology, pathophysiology and management. CNS Drugs (2005) 1.09
Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology (2003) 1.08
Antiretroviral-associated liver injury. Clin Liver Dis (2003) 0.97
Prospective study of new-onset seizures in patients with human immunodeficiency virus infection: etiologic and clinical aspects. Arch Neurol (1999) 0.96
Inhibition of human immunodeficiency virus (HIV-1) infection by diphenylhydantoin (dilantin) implicates role of cellular calcium in virus life cycle. Virology (1989) 0.93
HIV-related neurological syndromes reduce health-related quality of life. Can J Neurol Sci (2005) 0.90
CNS adverse events associated with antiepileptic drugs. CNS Drugs (2008) 0.89
Therapeutic dilemma: the use of anticonvulsants in HIV-positive individuals. Neurology (2000) 0.86
Valproic acid does not affect markers of human immunodeficiency virus disease progression. J Neurovirol (2006) 0.86
Anticonvulsant and antiretroviral interactions. Ann Pharmacother (2004) 0.86
Concurrent use of antiretrovirals and anticonvulsants in human immunodeficiency virus (HIV) seropositive patients. Curr Pharm Des (2003) 0.84
Anticonvulsant use in the treatment of manic syndromes in patients with HIV-1 infection. J Neuropsychiatry Clin Neurosci (1993) 0.80
The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes. Can J Psychiatry (2001) 0.80
Modulation of human immunodeficiency virus infection by anticonvulsant drugs. J Neurovirol (2006) 0.78
Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations. Eur J Neurol (2001) 0.78
The effect of divalproex sodium on HIV replication in vivo. J Neuropsychiatry Clin Neurosci (2007) 0.77
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis (2005) 5.20
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat Neurosci (2003) 2.66
Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci (2004) 2.64
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
The promise of minocycline in neurology. Lancet Neurol (2004) 2.06
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS (2009) 1.90
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med (2006) 1.69
A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci (2004) 1.66
HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci (2007) 1.64
The NK receptor NKp30 mediates direct fungal recognition and killing and is diminished in NK cells from HIV-infected patients. Cell Host Microbe (2013) 1.59
HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin (2008) 1.50
Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis (2011) 1.50
Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology (2004) 1.49
Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol (2006) 1.49
Comparative expression of human endogenous retrovirus-W genes in multiple sclerosis. AIDS Res Hum Retroviruses (2007) 1.41
The Direct Medical Costs of Late Presentation (<350/mm) of HIV Infection over a 15-Year Period. AIDS Res Treat (2011) 1.41
MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6 regulates astrocyte survival. FASEB J (2010) 1.39
Virologic and immunologic response to HAART, by age and regimen class. AIDS (2010) 1.34
Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. Am J Trop Med Hyg (2005) 1.33
Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr (2005) 1.32
West Nile virus-induced neuroinflammation: glial infection and capsid protein-mediated neurovirulence. J Virol (2007) 1.31
The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ (2003) 1.30
Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. J Clin Microbiol (2010) 1.28
Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med (2006) 1.25
Interleukin-1beta promotes oligodendrocyte death through glutamate excitotoxicity. Ann Neurol (2003) 1.24
Fatigue in HIV/AIDS is associated with depression and subjective neurocognitive complaints but not neuropsychological functioning. J Clin Exp Neuropsychol (2003) 1.22
Compartmentalization of the gut viral reservoir in HIV-1 infected patients. Retrovirology (2007) 1.19
Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology. Trends Neurosci (2009) 1.18
Brain microbial populations in HIV/AIDS: α-proteobacteria predominate independent of host immune status. PLoS One (2013) 1.15
Cytotoxic CD4+ T cells use granulysin to kill Cryptococcus neoformans, and activation of this pathway is defective in HIV patients. Blood (2006) 1.15
Acute disseminated encephalomyelitis: clinical and pathogenesis features. Neurol Clin (2008) 1.14
CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther (2010) 1.13
Regulation of neural cell survival by HIV-1 infection. Neurobiol Dis (2005) 1.13
Proteolytic processing of SDF-1alpha reveals a change in receptor specificity mediating HIV-associated neurodegeneration. Proc Natl Acad Sci U S A (2006) 1.12
Proteinase-activated receptors in the nervous system. Nat Rev Neurosci (2003) 1.12
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol (2012) 1.11
Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants? Biochim Biophys Acta (2010) 1.11
Evaluation of brief screening tools for neurocognitive impairment in HIV/AIDS: a systematic review of the literature. AIDS (2013) 1.10
The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. BMC Infect Dis (2011) 1.09
Peripheral nerve-derived HIV-1 is predominantly CCR5-dependent and causes neuronal degeneration and neuroinflammation. Virology (2005) 1.07
Disparities in the quality of HIV care when using US Department of Health and Human Services indicators. Clin Infect Dis (2014) 1.06
Neuroinflammation and endoplasmic reticulum stress are coregulated by crocin to prevent demyelination and neurodegeneration. J Immunol (2011) 1.05
Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis. J Immunol (2003) 1.05
Impaired neurosteroid synthesis in multiple sclerosis. Brain (2011) 1.05
HIV dementia patients exhibit reduced viral neutralization and increased envelope sequence diversity in blood and brain. AIDS (2002) 1.04
Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection. J Immunol (2005) 1.04
Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS. J Neurol Sci (2011) 1.03
Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS (2008) 1.02
NeuroAIDS: an evolving epidemic. Can J Neurol Sci (2009) 1.01
The clinical implications of high rates of intimate partner violence against HIV-positive women. J Acquir Immune Defic Syndr (2013) 1.01
RON-regulated innate immunity is protective in an animal model of multiple sclerosis. Ann Neurol (2005) 1.00
Rapid inflammasome activation in microglia contributes to brain disease in HIV/AIDS. Retrovirology (2014) 0.99
HIV-1 viral diversity and its implications for viral load testing: review of current platforms. Int J Infect Dis (2011) 0.99
Outpatient parenteral antibiotic therapy: evolution of the Calgary adult home parenteral therapy program. Clin Invest Med (2002) 0.98
Early life exposure to lipopolysaccharide suppresses experimental autoimmune encephalomyelitis by promoting tolerogenic dendritic cells and regulatory T cells. J Immunol (2009) 0.98
Glutamate binding and conformational flexibility of ligand-binding domains are critical early determinants of efficient kainate receptor biogenesis. J Biol Chem (2009) 0.97
Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDS (2003) 0.97
Hospitalizations after a decade of pneumococcal vaccination. N Engl J Med (2013) 0.97
CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy. FASEB J (2009) 0.97
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. J Acquir Immune Defic Syndr (2011) 0.97
Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis (2013) 0.97
Lentiviral neuropathogenesis: comparative neuroinvasion, neurotropism, neurovirulence, and host neurosusceptibility. J Virol (2002) 0.97
Hepatitis C virus core protein induces neuroimmune activation and potentiates Human Immunodeficiency Virus-1 neurotoxicity. PLoS One (2010) 0.96
Peripheral neuropathy in lentivirus infection: evidence of inflammation and axonal injury. AIDS (2004) 0.94
Characterizing the HIV epidemic in the prairie provinces. Can J Infect Dis Med Microbiol (2012) 0.93
Proteinase-activated receptor-2 exerts protective and pathogenic cell type-specific effects in Alzheimer's disease. J Immunol (2007) 0.93
Lentivirus infection causes neuroinflammation and neuronal injury in dorsal root ganglia: pathogenic effects of STAT-1 and inducible nitric oxide synthase. J Immunol (2005) 0.93
Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression. Brain (2007) 0.92
Inflammation and epithelial cell injury in AIDS enteropathy: involvement of endoplasmic reticulum stress. FASEB J (2011) 0.91
NeuroAIDS, drug abuse, and inflammation: building collaborative research activities. J Neuroimmune Pharmacol (2006) 0.91
Pill burden in HIV infection: 20 years of experience. Antivir Ther (2012) 0.91
Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis. PLoS One (2011) 0.91
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS (2008) 0.91
Human immunodeficiency virus type 1 envelope-mediated neuronal death: uncoupling of viral replication and neurotoxicity. J Virol (2003) 0.91
HIV-related neurological syndromes reduce health-related quality of life. Can J Neurol Sci (2005) 0.90